Skip to main content

View full-text article in PMC

. 2012 Jan 19;19(2):319–329. doi: 10.1007/s12350-011-9508-3

Table 3.

Change from baseline to 24-h post-dose in eGFR

eGFR, mL/minute/1.73 m²	Regadenoson		Placebo
eGFR, mL/minute/1.73 m²	n	Mean ± SD	n	Mean ± SD
All subjects
Baseline	330	41.96 ± 11.89	167	41.26 ± 11.27
Change from baseline	325	−0.43 ± 5.99	165	−0.34 ± 4.37
Stage 3 CKD
Baseline	284	44.69 ± 10.29	142	44.20 ± 9.06
Change from baseline	281	−0.60 ± 6.36	140	−0.46 ± 4.62
Stage 4 CKD
Baseline	46	25.09 ± 5.50	25	24.56 ± 7.34
Change from baseline	44	0.66 ± 2.47	25	0.32 ± 2.50

eGFR, Estimated glomerular filtration rate; SD, standard deviation.